"PMA DAYS" FOR FDA/SPONSOR RESOLUTION OF OUTSTANDING ISSUES ARE ENCOURAGED
This article was originally published in The Gray Sheet
Executive Summary
"PMA DAYS" FOR FDA/SPONSOR RESOLUTION OF OUTSTANDING ISSUES ARE ENCOURAGED in an Office of Device Evaluation "Blue Book" memorandum on closure of premarket approval applications. As part of an effort to ensure efficient and timely review of PMAs, ODE divisions "should consider setting aside specific 'PMA days' during which reviewers and managers will work with PMA applicants to resolve issues necessary to bring closure to these PMAs," the memo says.
You may also be interested in...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.